“Our ongoing SHIELD II Phase 3 trial for our promising lead product candidate, D-PLEX100, is progressing as anticipated,” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “We currently have 20 centers open, many of which have just recently begun recruiting patients, and we expect enrollment to ramp-up shortly. We anticipate having approximately 40 centers open by the end of 2023. Importantly, we continue to expect top-line results from SHIELD II in second half of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYPD:
- PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- PolyPid appoints Nurit Tweezer-Zaks to board of directors
- PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
- PolyPid price target raised to $10 from $2.50 at Barclays
- PolyPid initiated with a Buy at H.C. Wainwright
